Sex hormones and lipoprotein(a) concentration

Bibliography

• Berg K. A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand 1963;59(Suppl):369-82
   PubMedGoogle Scholar
• Kiechl S, Willeit J. The mysteries of lipoprotein(a) and cardiovascular disease revisited. J Am Coll Cardiol 2010;55:2168-70
   PubMed Web of Science ®Google Scholar
• Utermann G. Lp(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular basis of inherited disease. McGraw Hill, Inc., New York; 1995. p. 1887-912
   Google Scholar
• Acquati F, Hammer R, Ercoli B, Transgenic mice expressing a human apolipoprotein[a] allele. J Lipid Res 1999;40:994-1006
   PubMed Web of Science ®Google Scholar
• Boerwinkle E, Leffert CC, Lin J, Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60
   PubMed Web of Science ®Google Scholar
• Kraft HG, Kochl S, Menzel HJ, The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992;90:220-30
   PubMed Web of Science ®Google Scholar
• Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999;10:133-41
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5
   PubMed Web of Science ®Google Scholar
• Bennet A, Di Angelantonio E, Erqou S, Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008;168:598-608
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, ; For the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010. [Epub ahead of print]
   Google Scholar
• Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004;37:333-43
   PubMed Web of Science ®Google Scholar
• McLean JW, Tomlinson JE, Kuang WJ, cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7
   PubMed Web of Science ®Google Scholar
• Jenner JL, Ordovas JM, Lamon-Fava S, Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993;87:1135-41
   PubMed Web of Science ®Google Scholar
• Hancock MA, Boffa MB, Marcovina SM, Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003;278:23260-9
   PubMed Web of Science ®Google Scholar
• Rath M, Niendorf A, Reblin T, Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92
   PubMedGoogle Scholar
• Yamada S, Morishita R, Nakamura S, Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). Circulation 2000;102:1639-44
   PubMed Web of Science ®Google Scholar
• Romero FI, Khamashta MA, Hughes GR. Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis. Lupus 2000;9:206-9
   PubMed Web of Science ®Google Scholar
• Grainger DJ, Kemp PR, Liu AC, Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460-2
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008;19:369-77
   PubMed Web of Science ®Google Scholar
• Haque NS, Zhang X, French DL, CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000;102:786-92
   PubMed Web of Science ®Google Scholar
• Takami S, Yamashita S, Kihara S, Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998;97:721-8
   PubMed Web of Science ®Google Scholar
• Zhao SP, Xu DY. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res 2000;100:501-10
   PubMed Web of Science ®Google Scholar
• Schachinger V, Halle M, Minners J, Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1997;30:927-34
   PubMed Web of Science ®Google Scholar
• Bermudez V, Arraiz N, Aparicio D, Lipoprotein(a): from molecules to therapeutics. Am J Ther 2010;17:263-73
   PubMed Web of Science ®Google Scholar
• Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol 1997;17:1741-5
   PubMed Web of Science ®Google Scholar
• Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet 1995;9:424-31
   PubMed Web of Science ®Google Scholar
• Lawn RM. How often has Lp(a) evolved? Clin Genet 1996;49:167-74
   PubMed Web of Science ®Google Scholar
• Huby T, Afzal V, Doucet C, Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5′ distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice. Arterioscler Thromb Vasc Biol 2003;23:1633-9
   PubMed Web of Science ®Google Scholar
• Wang J, Boedeker J, Hobbs HH, White AL. Determinants of human apolipoprotein [a] secretion from mouse hepatocyte cultures. J Lipid Res 2001;42:60-9
   PubMed Web of Science ®Google Scholar
• Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-40
   PubMed Web of Science ®Google Scholar
• Becker L, Webb BA, Chitayat S, A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J Biol Chem 2003;278:14074-81
   PubMed Web of Science ®Google Scholar
• White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997;272:5048-55
   PubMed Web of Science ®Google Scholar
• Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 1993;91:1630-6
   PubMed Web of Science ®Google Scholar
• Boerwinkle E, Leffert CC, Lin J, Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60
   PubMed Web of Science ®Google Scholar
• Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest 1980;65:1483-90
   PubMed Web of Science ®Google Scholar
• Rader DJ, Cain W, Ikewaki K, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93:2758-63
   PubMed Web of Science ®Google Scholar
• Bonen DK, Hausman AM, Hadjiagapiou C, Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 1997;272:5659-67
   PubMed Web of Science ®Google Scholar
• Kraft HG, Menzel HJ, Hoppichler F, Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137-42
   PubMed Web of Science ®Google Scholar
• Trieu VN, McConathy WJ. A two-step model for lipoprotein(a) formation. J Biol Chem 1995;270:15471-4
   PubMed Web of Science ®Google Scholar
• Cain WJ, Millar JS, Himebauch AS, Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005;46:2681-91
   PubMed Web of Science ®Google Scholar
• Jialal I. Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein. Clin Chem 1998;44:1827-32
   PubMed Web of Science ®Google Scholar
• Rouy D, Duverger N, Lin SD, Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. Lipoprotein(a) assembly with human and rabbit apolipoprotein B. J Biol Chem 1998;273:1247-51
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996;122:89-95
   PubMed Web of Science ®Google Scholar
• Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992;89:1166-71
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31
   PubMed Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98
   PubMed Web of Science ®Google Scholar
• Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415-24
   PubMed Web of Science ®Google Scholar
• Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkerd E, Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: european prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75
   PubMed Web of Science ®Google Scholar
• Haring R, Volzke H, Steveling A, Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494-501
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5
   PubMed Web of Science ®Google Scholar
• Snyder PJ. In: Hardman JG, Limbird LE, editors, Goodman and Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw Hill, New York; 2001. p. 1635-45
   Google Scholar
• Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154:502-21
   PubMed Web of Science ®Google Scholar
• Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging 2009;4:397-412
   PubMed Web of Science ®Google Scholar
• Brawer MK. Testosterone replacement in men with andropause: an overview. Rev Urol 2004;6(Suppl 6):S9-15
   PubMedGoogle Scholar
• Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, Gilman AG, editors, Goodman & Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw-Hill, New York; 2001. p. 1597-635
   Google Scholar
• Haffner SM, Mykkanen L, Gruber KK, Lack of association between sex hormones and Lp(a) concentrations in American and Finnish men. Arterioscler Thromb 1994;14:19-24
   PubMed Web of Science ®Google Scholar
• Denti L, Pasolini G, Ablondi F, Valenti G. Correlation between plasma lipoprotein Lp(a) and sex hormone concentrations: a cross-sectional study in healthy males. Horm Metab Res 1994;26:602-8
   PubMed Web of Science ®Google Scholar
• Davoodi G, Amirezadegan A, Borumand MA, The relationship between level of androgenic hormones and coronary artery disease in men. Cardiovasc J Afr 2007;18:362-6
   PubMedGoogle Scholar
• Noyan V, Yucel A, Sagsoz N. The association of androgenic sex steroids with serum lipid levels in postmenopausal women. Acta Obstet Gynecol Scand 2004;83:487-90
   PubMed Web of Science ®Google Scholar
• Lambrinoudaki I, Christodoulakos G, Rizos D, Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 2006;154:907-16
   PubMed Web of Science ®Google Scholar
• Anderson RA, Wallace EM, Wu FC. Effect of testosterone enanthate on serum lipoproteins in man. Contraception 1995;52:115-19
   PubMed Web of Science ®Google Scholar
• Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996;77:1244-7
   PubMed Web of Science ®Google Scholar
• Ozata M, Yildirimkaya M, Bulur M, Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996;81:3372-8
   PubMed Web of Science ®Google Scholar
• Zang H, Carlstrom K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 2006;86:136-44
   PubMed Web of Science ®Google Scholar
• Barnhart KT, Freeman E, Grisso JA, The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84:3896-902
   PubMed Web of Science ®Google Scholar
• Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy. Maturitas 2004;47:123-9
   PubMed Web of Science ®Google Scholar
• Teruel JL, Lasuncion MA, Rivera M, Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997;29:569-75
   PubMed Web of Science ®Google Scholar
• Hartgens F, Rietjens G, Keizer HA, Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a). Br J Sports Med 2004;38:253-9
   PubMed Web of Science ®Google Scholar
• Hislop MS, St Clair Gibson A, Lambert MI, Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis 2001;159:425-32
   PubMed Web of Science ®Google Scholar
• Albers JJ, Taggart HM, Applebaum-Bowden D, Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 1984;795:293-6
   PubMed Web of Science ®Google Scholar
• Crook D, Sidhu M, Seed M, Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992;92:41-7
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Kliesch S, Nieschlag E, Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). J Clin Endocrinol Metab 1997;82:3367-72
   PubMed Web of Science ®Google Scholar
• Berglund L, Carlstrom K, Stege R, Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996;81:2633-7
   PubMed Web of Science ®Google Scholar
• Denti L, Pasolini G, Cortellini P, Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem 1996;42(8 Pt 1):1176-81
   PubMed Web of Science ®Google Scholar
• Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-55
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Murphy LC, San Foo M, High-affinity antioestrogen binding site distinct from the oestrogen receptor. Nature 1980;288:273-5
   PubMed Web of Science ®Google Scholar
• de Medina P, Silvente-Poirot S, Poirot M. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 2009;5:1066-7
   PubMed Web of Science ®Google Scholar
• Kedjouar B, de Medina P, Oulad-Abdelghani M, Molecular characterization of the microsomial tamoxifen binding site. J Biol Chem 2004;279:34048-61
   PubMed Web of Science ®Google Scholar
• de Medina P, Favre G, Poirot M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anti Cancer Agents 2004;4:491-508
   PubMedGoogle Scholar
• de Medina P, Payre BL, Bernad J, Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 2004;308:1165-73
   PubMed Web of Science ®Google Scholar
• Eisen A, Trudeau M, Shelley W, Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008;34:157-74
   PubMed Web of Science ®Google Scholar
• Hiraga T, Shimokawa K, Murase T, Yokoyama M. Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer. Endocr J 1993;40:507-13
   PubMed Web of Science ®Google Scholar
• Usui S, Suzuki K, Yamanaka H, Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques. Clin Chim Acta 2002;317:133-43
   PubMed Web of Science ®Google Scholar
• Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. BMJ 1991;303:694
   PubMed Web of Science ®Google Scholar
• Mendoza S, Velazquez E, Osona A, Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein[a]. J Lab Clin Med 1994;123:837-41
   PubMed Web of Science ®Google Scholar
• Shewmon DA, Stock JL, Rosen CJ, Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-93
   PubMed Web of Science ®Google Scholar
• Kim CJ, Jang HC, Cho DH, Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81
   PubMed Web of Science ®Google Scholar
• Kim CJ, Min YK, Ryu WS, Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 1996;156:1693-700
   PubMed Web of Science ®Google Scholar
• Schram JH, Boerrigter PJ, The TY. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism. Maturitas 1995;22:121-30
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Puolakka J, Pyorala T, Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996;16:1215-21
   PubMed Web of Science ®Google Scholar
• Hanggi W, Lippuner K, Riesen W, Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997;104:708-17
   PubMedGoogle Scholar
• Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 1997;17:1822-9
   PubMed Web of Science ®Google Scholar
• Walsh BW, Kuller LH, Wild RA, Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51
   PubMed Web of Science ®Google Scholar
• Espeland MA, Marcovina SM, Miller V, Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998;97:979-86
   PubMed Web of Science ®Google Scholar
• Farish E, Barnes JF, Fletcher CD, Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Menopause 1999;6:98-104
   PubMed Web of Science ®Google Scholar
• Mijatovic V, van der Mooren MJ, Kenemans P, Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999;6:134-7
   PubMed Web of Science ®Google Scholar
• Abbey M, Owen A, Suzakawa M, Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999;33:259-69
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Simon JA, Vittinghoff E, Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52
   PubMed Web of Science ®Google Scholar
• Seed M, Sands RH, McLaren M, The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam Pract 2000;17:497-507
   PubMed Web of Science ®Google Scholar
• Ossewaarde ME, Bots ML, Bak AA, Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. Maturitas 2001;39:209-16
   PubMed Web of Science ®Google Scholar
• Falco C, Tormo G, Estelles A, Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica 2001;86:92-8
   PubMed Web of Science ®Google Scholar
• Smolders RG, Vogelvang TE, Mijatovic V, A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;41:105-14
   PubMed Web of Science ®Google Scholar
• Perry W, Wiseman RA. Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. Maturitas 2002;42:157-64
   PubMed Web of Science ®Google Scholar
• Gregoriou O, Christodoulakos G, Siristatidis C, Continuous combined replacement therapy in postmenopausal women: effect on plasma lipoproteins, bone mass and the endometrium. Hormones (Athens) 2002;1:239-44
   PubMedGoogle Scholar
• Prelevic GM, Kwong P, Byrne DJ, A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945-51
   PubMed Web of Science ®Google Scholar
• Kwok S, Selby PL, McElduff P, Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol (Oxf) 2004;61:760-7
   PubMed Web of Science ®Google Scholar
• Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol Endocrinol 2004;18:244-57
   PubMed Web of Science ®Google Scholar
• Bukowska H, Stanosz S, Zochowska E, Does the type of hormone replacement therapy affect lipoprotein(a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005;54:72-8
   PubMed Web of Science ®Google Scholar
• Ko HS, Kim CJ, Ryu WS. Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women. Korean J Intern Med 2005;20:33-9
   PubMedGoogle Scholar
• Bayrak A, Aldemir DA, Bayrak T, The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet 2006;274:289-96
   PubMedGoogle Scholar
• Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 2008;6:928-34
   PubMed Web of Science ®Google Scholar
• Perrone G, Capri O, Galoppi P, Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. Gynecol Obstet Invest 2009;68:33-9
   PubMed Web of Science ®Google Scholar
• Perrone G, Stefanutti C, Galoppi P, Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. Int J Fertil Menopausal Stud 1996;41:509-15
   PubMed Web of Science ®Google Scholar
• Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601
   PubMed Web of Science ®Google Scholar
• Decensi A, Robertson C, Ballardini B, Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 1999;35:596-600
   PubMed Web of Science ®Google Scholar
• Shewmon DA, Stock JL, Abusamra LC, Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism 1994;43:531-2
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Ehnholm C, Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33
   PubMed Web of Science ®Google Scholar
• Liberopoulos E, Karabina SA, Tselepis A, Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 2002;62(2):115-20
   PubMed Web of Science ®Google Scholar
• Kusama M, Miyauchi K, Aoyama H, Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 2004;88:1-8
   PubMed Web of Science ®Google Scholar
• Elisaf MS, Bairaktari ET, Nicolaides C, Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510-13
   PubMed Web of Science ®Google Scholar
• Wasan KM, Goss PE, Pritchard PH, The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-15
   PubMed Web of Science ®Google Scholar
• Rymer J, Crook D, Sidhu M, Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol (Copenh) 1993;128:259-62
   PubMedGoogle Scholar
• Farish E, Barnes JF, Rolton HA, Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994;20:215-19
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos S, Petrogiannopoulos C, Gagos S, The influence of 5-year therapy with tibolone on the lipid profile in postmenopausal women with mild hypercholesterolemia. Gynecol Endocrinol 2004;18:227-32
   PubMed Web of Science ®Google Scholar
• Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-6
   PubMed Web of Science ®Google Scholar
• Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008;101(Suppl):B44-7
   PubMed Web of Science ®Google Scholar
• Soma M, Fumagalli R, Paoletti R, Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 1991;337:612
   PubMed Web of Science ®Google Scholar
• Melichar B, Kalabova H, Krcmova L, Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res 2009;29:3337-46
   PubMed Web of Science ®Google Scholar
• Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol 2007;166:511-17
   PubMed Web of Science ®Google Scholar
• Cheung MC, Albers JJ, Wahl PW, Hazzard WR. High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. Atherosclerosis 1980;35:215-28
   PubMed Web of Science ®Google Scholar
• Taggart HM, Applebaum-Bowden D, Haffner S, Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982;31:1147-52
   PubMed Web of Science ®Google Scholar
• Jockenhovel F, Bullmann C, Schubert M, Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999;48:590-6
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Foster DM, Zech LA, The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262-7
   PubMed Web of Science ®Google Scholar
• Walsh BW, Schiff I, Rosner B, Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204
   PubMed Web of Science ®Google Scholar
• Love RR, Wiebe DA, Feyzi JM, Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9
   PubMed Web of Science ®Google Scholar
• Morales M, Santana N, Soria A, Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 1996;40:265-70
   PubMed Web of Science ®Google Scholar
• Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-5
   PubMed Web of Science ®Google Scholar
• Kataja V, Hietanen P, Joensuu H, The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer – a randomised study. Breast Cancer Res Treat 2002;76(Suppl 1):S156
   Google Scholar
• Wojtacki J, Lesniewski-Kmak K, Pawlak W, Anastrozole therapy and lipid profile: an update [abstract 297]. Eur J Cancer 2004;40(Suppl 2):142
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Bjarnason K, Haarbo J, Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
   PubMed Web of Science ®Google Scholar
• Tenover L. The androgen-deficient aging male: current treatment options. Rev Urol 2003;5(Suppl 1):S22-8
   PubMedGoogle Scholar
• Bagatell CJ, Bremner WJ. Androgens in men – uses and abuses. N Engl J Med 1996;334:707-14
   PubMed Web of Science ®Google Scholar
• Reyes-Fuentes A, Veldhuis JD. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol Metab Clin North Am 1993;22:93-124
   PubMed Web of Science ®Google Scholar
• Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 2003;79(Suppl 3):1659-61
   PubMed Web of Science ®Google Scholar
• Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep 2002;4:377-87
   PubMedGoogle Scholar
• Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry 1999;11:223-31
   PubMedGoogle Scholar
• Brawer MK. Testosterone replacement therapy in men with andropause: an overview. Rev Urol 2004;6(Suppl 6):S9-15
   PubMedGoogle Scholar
• Raynaud JP. Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol 2009;114:96-105
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59
   PubMed Web of Science ®Google Scholar
• Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron JA, Correia N, Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32
   PubMed Web of Science ®Google Scholar
• Newcomb PA, Titus-Ernstoff L, Egan KM, Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-15
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
   PubMed Web of Science ®Google Scholar
• Doherty JA, Cushing-Haugen KL, Saltzman BS, Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:139. e1-7
   PubMed Web of Science ®Google Scholar
• Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217
   PubMed Web of Science ®Google Scholar
• Tong PC, Ho CS, Yeung VT, Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab 2005;90:6418-23
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:2074-9
   PubMed Web of Science ®Google Scholar
• Kanayama G, Brower KJ, Wood RI, Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend 2010;109:6-13
   PubMed Web of Science ®Google Scholar
• Simon JA, Hsia J, Cauley JA, Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84
   PubMed Web of Science ®Google Scholar
• Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680-90
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
   PubMed Web of Science ®Google Scholar